Early DMARD Initiation Benefits in Psoriatic Arthritis Save
Mease et al has published the results of a cohort study showing early initiation of disease-modifying antirheumatic drugs (DMARDs) in patients with psoriatic arthritis (PsA) resulted in better outcomes compared to late initiation.
A total of 291 PsA patients from the CorEvitas PsA/Spondyloarthritis Registry were studies. Early a.nd late DMARD initiators were based on whether first DMARD treatment occurred ≤1 year or >1 year after a PsA diagnosis. Outcomes included change in disease activity and patient-reported outcomes (PROs) from initiation to the six-month follow-up.
The mean time from diagnosis to DMARD initiation was 0.2 years in early initiators (n = 229, 79%) and 8.6 years in late initiators (n = 62, 21%). Early DMARD initiaion was associated with greater:
- MDA - minimal disease activity (adjusted risk ratio 2.01,1.03–4.40)
- Change in Clinical Disease Activity Index (β −3.4, 95% CI −6.2 to −0.49)
Nonetheless, both early and late initiation of DMARD therapy experienced improvements throughout all disease activity and PROs over the six months of treatment. .
ADD THE FIRST COMMENT
Disclosures
The author has no conflicts of interest to disclose related to this subject
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.